research Myeloproliferative disorder associated with alopecia universalis
Ruxolitinib helped regrow hair in a woman with a blood disorder and complete hair loss.
Search
for
Sort by
Research
990-1000 / 1000+ resultsresearch Efficacy and safety of anthralin in combination with diphenylcyclopropenone in the treatment of alopecia areata: a retrospective case series
Combining DPCP and anthralin helps regrow hair in some alopecia areata patients.
research Lichen planopilaris after hair transplantation
Oral minoxidil improved male baldness, but had side effects; certain antibiotics effectively treated a rare scalp condition; hair transplants might trigger another scalp condition.
research Fatigue, alopecia and stomatitis among patients with breast cancer receiving cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis
Breast cancer patients taking CDK4/6 inhibitors are more likely to experience fatigue, hair loss, and mouth sores.
research A Case of Topical Ruxolitinib Treatment Failure in Alopecia Areata
Topical ruxolitinib failed to regrow hair in a 66-year-old with alopecia areata.
research Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors
Cancer patients treated with immune checkpoint inhibitors may develop alopecia, but some hair regrowth is possible with treatment.
research Topical Treatment of Alopecia Areata
DNCB helps regrow hair in alopecia areata patients, but safer alternatives are needed.
research Incidence of alopecia from endocrine therapies in cancer
Hair loss is a common, often overlooked side effect of hormone treatments for breast and prostate cancer.
research Reversible Anagen Effluvium Induced by Azathioprine: A Rare Adverse Effect Case Report
Stopping azathioprine led to full hair regrowth and recovery in 2.5 months.
research Alopecia/hair loss in all patients treated with trastuzumab and paclitaxel: myth or reality?
Most patients treated with trastuzumab and paclitaxel experience some hair loss, but it's usually not severe.